Recommended videos
Aegerion Pharmaceuticals AEGR
16 views
Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. Aegerion Pharmaceuticals Incorporated - AEGR - provided a clinical update on its lomitapide. Aegerion reported that the 78-week data from its pivotal Phase III clinical trial is consistent with data previously reported at the 26- and 56-week time points
Date:
2012. 01. 08.
Add to list
Recommended videos

Facebook
X / Twitter
Tumblr
Reddit
Telegram
WhatsApp
LinkedIn
E-mail